Methylene-tetrahydrofolate reductase (MTHFR) single nucleotide polymorphism (SNP) in gemcitabine (gem)/cisplatin (cis)-treated non-small-cell lung cancer (NSCLC) patients (p)

Abstract

7163 Background:: MTHFR 677 SNP results in an adenine to valine (C-T) substitution. Individuals homozygous for 677 TT have lower genomic DNA methylation than persons with wild-type (CC). Since MTHFR 677 SNP is involved in folate metabolism, DNA methylation and DNA repair, we have examined its potential influence on outcome and toxicity in gem/cis-treated NSCLC Methods: 208 stage IV NSCLC p were included from August 2001 to July 2002. TaqMan 5' nuclease assay was used to examine MTHFR 677 SNP from baseline peripheral blood lymphocytes Results: p characteristics: median age: 61; 91% male; PS 0: 23.4%, 1: 62.7%, 2: 13.9%; adenocarcinoma: 43.1%, pleural effusion: 16%. Overall: response rate (RR) 38.6%; time to progression (TTP) 6 months (m); median survival (MS) 10.56 m. MTHFR 677 genotypes: CC 30.3%; CT 57.4%; TT 12.3%. By genotype: RR: CC 35.9%, CT: 43.6%, TT 42.3%; TTP: CC 7.4 m, CT 5.4 m, TT 5.2 m; MS: CC 11.2 m, CT 10.3 m, TT 9.8 m. Toxicity analysis is ongoing. Conclusions: No differences in outcome were observed according to MTHFR 677 SNP, suggesting that MTHFR 677 SNP does not by itself play an important role in outcome with gem/cis. Complete data, including toxicity, will be presented. No significant financial relationships to disclose.